A Phase 3 interventional study of Lacosamide and Levetiracetam in Epilepsy, Partial, sponsored by UCB Pharma. Terminated at 7 sites in 3 countries. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2017-08-28.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing lacosamide in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Lacosamide · Epilepsies, Partial.
Among the 11 studies testing lacosamide in Epilepsies, Partial, this one is the 11th largest by enrollment, is the only one that started in 2011, is one of 4 in phase 3, and was the 10th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 11 studies testing lacosamide in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Lacosamide: first FDA approval 2008 (VIMPAT), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 45 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 5 · Phase 4 4
First in 2001; this study’s year is marked. 1 started in 2011.
This study's enrollment of 11 is below the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 100 across the 11 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 5 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
29 studies in Epilepsies, Partial by UCB S.A.: none open now, none under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 29 studies in Epilepsies, Partial by UCB S.A., this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2011, is one of 11 in phase 3, and was the 25th registered.
UCB S.A.’s Epilepsies, Partial studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing lacosamide in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 29 in Epilepsies, Partial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the trial is to investigate whether changes in lipids and hormonal parameters can be observed in blood when Carbamazepine treatment is replaced with Lacosamide treatment, while Levetiracetam treatment remains unchanged.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
commercial 50 mg (pinkish) and 100 mg (yellow) tablets
Drug: Lacosamide · Drug: Levetiracetam
4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
Also known as: Vimpat
Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
Also known as: Keppra
Change in Serum Sex Hormone Binding Globulin (SHBG) From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)
Due to premature termination of enrollment prior to achieving the planned sample size (a total of 28 subjects), this primary safety variable was assessed for descriptive purposes only. A negative value indicates an improvement.
Time frame: From Day 1 (Baseline) to Day 84 (Treatment Period End)
Change in Sex Hormone Calculated Free Androgen Index Levels From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)
The change in sex hormone calculated free androgen index (100 x Testosterone/sex hormone binding globulin) levels from Baseline to the end of Maintenance Period was summarized descriptively by visit. A negative value indicates an improvement.
Time frame: From Day 1 (Baseline) to Day 84 (Treatment Period End)
Change in Serum Thyroid Hormone Free Thyroxine Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)
The change in the serum thyroid hormone free thyroxine level from Baseline to the end of the Maintenance Period was summarized descriptively by visit.
Time frame: From Day 1 (Baseline) to Day 84 (Treatment Period End)
Change in Total Cholesterol Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period)
The change in total cholesterol levels from Baseline to the end of the Maintenance Period was summarized descriptively by visit. A negative value indicates an improvement.
Time frame: From Day 1 (Baseline) to Day 84 (Treatment Period End)
The study was conducted at 5 sites across Austria (1 site), Germany (3 sites), and Spain (1 site).
| Milestone | Lacosamide |
|---|---|
| Started | 11 |
| Completed | 10 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Due to premature termination of enrollment prior to achieving the planned sample size (a total of 28 subjects), this primary safety variable was assessed for descriptive purposes only. A negative value indicates an improvement.
| nmol/L | Lacosamide |
|---|---|
| Change in Serum Sex Hormone Binding Globulin (SHBG) From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period) | -12.80 (-20.3 to 4.9) |
The change in sex hormone calculated free androgen index (100 x Testosterone/sex hormone binding globulin) levels from Baseline to the end of Maintenance Period was summarized descriptively by visit. A negative value indicates an improvement.
| Free Androgen Index | Lacosamide |
|---|---|
| Change in Sex Hormone Calculated Free Androgen Index Levels From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period) | 9.493 (2.39 to 26.46) |
The change in the serum thyroid hormone free thyroxine level from Baseline to the end of the Maintenance Period was summarized descriptively by visit.
| pmol/L | Lacosamide |
|---|---|
| Change in Serum Thyroid Hormone Free Thyroxine Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period) | 2.70 (1.5 to 5.5) |
The change in total cholesterol levels from Baseline to the end of the Maintenance Period was summarized descriptively by visit. A negative value indicates an improvement.
| mmol/L | Lacosamide |
|---|---|
| Change in Total Cholesterol Level From Baseline to Treatment Period End (Comprised of a 4-week Titration Period and an 8-week Maintenance Period) | -0.540 (-1.46 to 0.11) |
Collected over Treatment Emergent Adverse Event were reported from Baseline until the Safety Follow-up Visit (two weeks after end of Treatment Period).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lacosamide | — | 0/11 (0%) | 5/11 (45.5%) |
| Event | Lacosamide |
|---|---|
| FatigueGeneral disorders | 1/11 |
| BronchitisInfections and infestations | 1/11 |
| InfluenzaInfections and infestations | 1/11 |
| ConvulsionNervous system disorders | 1/11 |
| Disturbance in attentionNervous system disorders | 1/11 |
| ParaesthesiaNervous system disorders | 1/11 |
| Partial seizuresNervous system disorders | 1/11 |
| TremorNervous system disorders | 1/11 |
| AggressionPsychiatric disorders | 1/11 |
| Hot flushVascular disorders | 1/11 |
The Baseline Analysis Population refers to the Safety Set (SS). The SS consists of all patients who received at least 1 dose of Lacosamide.
| Age, Continuous(years) | Lacosamide |
|---|---|
| Mean | 31.5 ± 5.9 |
| Age, Categorical(Participants) | Lacosamide |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 11 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Lacosamide |
|---|---|
| Female | 0 |
| Male | 11 |
| Race/Ethnicity, Customized(participants) | Lacosamide |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Black or African American | 0 |
| Native Hawaiin or other Pacific Islander | 0 |
| White | 9 |
| Other/Mixed | 1 |
| Weight(kilograms) | Lacosamide |
|---|---|
| Mean | 82.81 ± 16.25 |
| Height(centimeters) | Lacosamide |
|---|---|
| Mean | 178.05 ± 10.14 |
| Body Mass Index(kilogram per square meter) | Lacosamide |
|---|---|
| Mean | 25.89 ± 3.01 |
The record gives a start of Jul 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 1 year 8 months after primary completion. A results delay was requested in Dec 2013.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lacosamide · Levetiracetam